Table 2.
Comparison of treatment response between CSM-TACE group and cTACE group
| Items | M1 | M3 | M6 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| CSM-TACE group | cTACE group | P-value | CSM-TACE group | cTACE group | P-value | CSM-TACE group | cTACE group | P-value | |
| Number of assessed patients | 107 | 124 | 82 | 55 | 54 | 45 | |||
| CR | 13 (12.1) | 10 (8.1) | 0.301 | 16 (19.5) | 3 (5.5) | 0.020 | 9 (16.7) | 3 (6.7) | 0.129 |
| PR | 64 (59.8) | 48 (38.7) | 0.001 | 47 (57.3) | 22 (40.0) | 0.047 | 29 (53.7) | 18 (40.0) | 0.174 |
| SD | 19 (17.8) | 50 (40.3) | <0.001 | 5 (6.1) | 21 (38.1) | <0.001 | 10 (18.5) | 15 (33.3) | 0.091 |
| PD | 11 (10.3) | 16 (12.9) | 0.536 | 14 (17.1) | 9 (16.4) | 0.913 | 6 (11.1) | 9 (20.0) | 0.219 |
| ORR | 77 (71.9) | 58 (46.8) | <0.001 | 63 (76.8) | 25 (45.5) | <0.001 | 38 (70.4) | 21 (46.7) | 0.017 |
| DCR | 96 (89.7) | 108 (87.1) | 0.536 | 68 (82.9) | 46 (83.6) | 0.913 | 48 (88.9) | 36 (80.0) | 0.219 |
| Number of assessed nodules | 179 | 211 | 131 | 91 | 86 | 77 | |||
| CR | 30 (16.8) | 26 (12.3) | 0.213 | 32 (24.4) | 12 (13.2) | 0.039 | 23 (26.7) | 15 (19.5) | 0.274 |
| PR | 31 (17.3) | 23 (10.9) | 0.067 | 22 (16.8) | 12 (13.2) | 0.463 | 34 (39.5) | 24 (31.2) | 0.265 |
| SD | 87 (48.6) | 99 (46.9) | 0.740 | 62 (47.3) | 41 (45.1) | 0.738 | 29 (33.8) | 38 (49.4) | 0.043 |
| PD | 31 (17.3) | 63 (29.9) | 0.004 | 15 (11.5) | 26 (28.5) | 0.001 | 0 (0.0) | 0 (0.0) | – |
| ORR | 61 (34.1) | 49 (23.2) | 0.018 | 54 (41.2) | 24 (26.4) | 0.023 | 57 (66.2) | 39 (50.6) | 0.043 |
| DCR | 148 (82.7) | 148 (70.1) | 0.004 | 116 (88.5) | 65 (71.5) | 0.001 | 86 (100.0) | 77 (100.0) | – |
Notes: Data was presented as count (%). Comparison between two groups was determined by Chi-square test. P-value <0.05 was considered significant, and the significant results were shown in boldface. “–” indicated that the data was unable to be compared due to lack of events.
Abbreviations: CSM-TACE, transarterial chemoembolization with CalliSpheres® microspheres; cTACE, conventional transarterial chemo-embolization; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; ORR, objective response rate; DCR, disease control rate.